“I am thrilled to be a part of this endeavor and welcome the challenge.”
Igor Lacik, PhD, Polymer Institute of the Slovak Academy of Sciences, Bratislava, Slovakia
The Chicago Diabetes Project is currently conducting a phase III licensure trial in islet transplantation to successfully apply for a biological license for islet transplantation. This will allow islet transplantation to be recognized as standard medical care for brittle type I diabetic patients, and is mandatory for reimbursement by medical insurances.
We are also planning a phase I/II clinical trial with encapsulated human islet allotransplantation (link to definition) in brittle type I diabetic patients. This will be the first clinical trial of this nature conducted in an academic center in the US, and will ultimately answer the question whether the concept of microencapsulation of islet grafts works in humans or not.
To control patients' blood-sugar levels, the Chicago Diabetes Project plans to produce an unlimited source of islet cells in the laboratory that are suitable and safe for transplantation in humans. By delivering a limitless source of pancreatic islet cells, members of the Chicago Diabetes Project team offers hope to the millions of patients throughout the world a chance at living a normal and healthy life free of managing and controlling diabetes.
Your contribution will help doctors and scientists all over the world to bring an end to diabetes of all types. Together we can brighten the lives of people across the globe.
